BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions
The Oncologist · 08.05.2026 · 31 (6)
DOI: 10.1093/oncolo/oyag165 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 28.04.2026. Verfasst von Samer Al Hadidi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma, Waldenstrom's, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT So…. Die Arbeit nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Myeloma, Waldenstrom's, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX 75390-8565, United States.
ORCID-Profile: Samer Al Hadidi
Zitieren
APA
Al Hadidi, S., Khan, A. M., Afrough, A., & Anderson, L. D. (2026). BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions. The Oncologist, 31(6). https://doi.org/10.1093/oncolo/oyag165
Vancouver
Al Hadidi S, Khan AM, Afrough A, Anderson LD. BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions. The Oncologist. 2026;31(6). doi:10.1093/oncolo/oyag165
BibTeX
@article{AlHadidi2026,
author = {Al Hadidi, Samer and Khan, Adeel M and Afrough, Aimaz and Anderson, Larry D},
title = {BCMA-targeted bispecific antibodies in relapsed/refractory multiple myeloma: three approvals, many questions},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {6},
doi = {10.1093/oncolo/oyag165}
}
EUVIMED